The skeletal consequences of growth hormone therapy in dialyzed children: A randomized trial

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 5, 2013, Pages 824-832

  Bacchetta, Justine ^a   Wesseling Perry, Katherine ^a   Kuizon, Beatriz ^a   Pereira, Renata C ^a   Gales, Barbara ^a   Wang, He Jing ^b   Elashoff, Robert ^b   Salusky, Isidro B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; GROWTH HORMONE; BIOLOGICAL MARKER; HUMAN GROWTH HORMONE; PARATHYROID HORMONE; PTH PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BONE BIOPSY; BONE MINERALIZATION; BONE TURNOVER; CHILD; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HISTOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MALE; MORPHOMETRICS; OSSIFICATION; OSTEODYSTROPHY; PERITONEAL DIALYSIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SECONDARY HYPERPARATHYROIDISM; ANALYSIS OF VARIANCE; BIOPSY; BLOOD; BODY HEIGHT; BONE; BONE DEVELOPMENT; COMPLICATION; CONTROLLED STUDY; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; PATHOLOGY; RENAL OSTEODYSTROPHY; TIME; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BIOPSY; BODY HEIGHT; BONE AND BONES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; KIDNEY FAILURE, CHRONIC; LOS ANGELES; MALE; OSTEOGENESIS; PARATHYROID HORMONE; PERITONEAL DIALYSIS; RECOMBINANT PROTEINS; RENAL OSTEODYSTROPHY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877668649     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00330112     Document Type: Article

References (30)

1. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS): 2005 Annual Report. 2005. Available at: https:// web.emmes.com/study/ped/annlrept/annlrept2005.pdf. Accessed January 2012
2. Haffner D, Schaefer F, Nissel R, Wühl E, Tönshoff B, Mehls O; German Study Group for Growth Hormone TreatmentinChronic Renal Failure: Effect of growth hormone treatment on the adult height of children with chronic renal failure. N Engl J Med 343: 923-930, 2000
3. Vimalachandra D, Hodson EM, Willis NS, Craig JC, Cowell C, Knight JF: Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev (3): CD003264, 2006
4. Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, Wit JM, Wolff ED, de Jong MC, Donckerwolcke RA, Abbad NC, Bot A, Blum WF, et al: Placebo-controlled, double-blind, crossover trial of growth hormone treatment in prepubertal children with chronic renal failure. Lancet 338: 585-590, 1991
5. Nissel R, Lindberg A, Mehls O, Haffner D; Pfizer International Growth Database (KIGS) International Board: Factors predicting the near-final height in growth hormone-treated children and adolescents with chronickidneydisease. J Clin Endocrinol Metab 93: 1359-1365, 2008
6. Lanes R, Gunczler P, Orta N, Bosquez M, Scovino R, Dominguez L, Esaa S, Weisinger JR: Changes in bone mineral density, growth velocity and renal function of prepubertal uremic children during growth hormone treatment. Horm Res 46: 263-268, 1996
7. Boot AM, Nauta J, deJong MC, Groothoff JW, Lilien MR, van Wijk JA, Kist-van Holthe JE, Hokken-Koelega AC, Pols HA, de Muinck Keizer-Schrama SM: Bone mineral density, bone metabolism and body compositionof children withchronic renal failure, with and without growth hormone treatment. Clin Endocrinol (Oxf) 49: 665-672, 1998
8. Crompton CH; Australian and New Zealand Paediatric Ne-phrology Association: Long-term recombinant human growth hormone use in Australian children with renal disease. Ne-phrology (Carlton) 9: 325-330, 2004
9. Müller-Wiefel D, Frisch H, Tulassay T, Bell L, Zadik Z: Treatment of growth failure with growth hormone in children with chronic kidney disease: An open-label long-term study. Clin Nephrol 74: 97-105, 2010
10. Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, Salusky IB: Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53: 205-211, 1998
11. Chesney RW, Moorthy AV, Eisman JA, Jax DK, Mazess RB, DeLuca HF: Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy. N Engl J Med 298: 238-242, 1978
12. Baroncelli GI, Bertelloni S, Sodini F, Saggese G: Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency. J Pediatr Endocrinol Metab 16[Suppl 2]: 327-335, 2003
13. Murray RD, Adams JE, Shalet SM: Adults with partial growth hormone deficiency have an adverse body composition. J Clin Endocrinol Metab 89: 1586-1591, 2004
14. Colao A, Di Somma C, Pivonello R, Loche S, Aimaretti G, Cerbone G, Faggiano A, Corneli G, Ghigo E, Lombardi G: Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 84: 1919-1924, 1999
15. Salusky IB, Goodman WG: Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy. Kidney Int 48: 657-665, 1995
16. Sanchez CP, Goodman WG, Brandli D, Goldenhersh M, Murray C, Carlton E, Hahn T, Salusky IB: Skeletal response to recombi-nant human growth hormone (rhGH) in children treated with long-term corticosteroids. J Bone Miner Res 10: 2-6, 1995
17. Hernandez JD, Wesseling K, Pereira R, Gales B, Harrison R, Salusky IB: Technicalapproach to iliac crest biopsy. ClinJAm Soc Nephrol 3[Suppl 3]: S164-S169, 2008
18. Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Ettenger RB, Goodman WG: Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 53: 1358-1364, 1998
19. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR; Report of the ASBMR Histo-morphometry Nomenclature Committee: Bone histo-morphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2: 595-610, 1987
20. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
21. Salusky IB, Fine RN, Nelson P, Blumenkrantz MJ, Kopple JD: Nutritional status of children undergoing continuous ambulatory peritoneal dialysis. Am J Clin Nutr 38: 599-611, 1983
22. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46: S1-S121, 2005
23. Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schröder C, Zurowska A, Ekim M; European Pediatric Dialysis Working Group (EPDWG): Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21: 151-159, 2006
24. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D'Amour P: A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44: 805-809, 1998
25. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46: 1160-1166, 1994
26. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Jüppner H, Salusky IB: Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79: 112-119, 2011
27. Courtland HW, Sun H, Beth-On M, Wu Y, Elis S, Rosen CJ, Yakar S: Growth hormone mediates pubertal skeletal development independent of hepatic IGF-1 production. J Bone Miner Res 26: 761-768, 2011
28. Salusky IB, Goodman WG, Horst R, Segre GV, Kim L, Norris KC, Adams JS, Holloway M, Fine RN, Coburn JW: Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am J Kidney Dis 16: 126-132, 1990
29. Wesseling-Perry K, Harkins GC, Wang HJ, Sahney S, Gales B, Elashoff RM, Jüppner H, Salusky IB: Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatr Nephrol 24: 1355-1361, 2009
30. Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, Massart C, Moe SM, Monge M, Souberbielle JC: Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kid Dis. 51: 987-995, 2008